STAT+: A turning point for pancreatic cancer patients

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We’re catching up on plenty of ASCO news from over the weekend, including detailed daraxonrasib results in pancreatic cancer, and a Chinese lung cancer therapy that continues to outperform expectations.

Also, a decades-old peptide beloved by biohackers has become a lightning rod in a battle over FDA regulation of these substances.

Continue to STAT+ to read the full story…

المصدر: STAT News